BeiGene
BGNE
#926
Rank
NZ$36.53 B
Marketcap
$326.36
Share price
-2.08%
Change (1 day)
6.88%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -NZ$1.45 Billion

According to BeiGene 's latest financial reports the company's current earnings are NZ$3.09 Billion. In 2023 the company made an earning of -NZ$2.07 Billion, an increase over its 2022 earnings that were of -NZ$3.07 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -NZ$1.45 Billion-30.19%
2023 -NZ$2.07 Billion-32.52%
2022 -NZ$3.07 Billion24.39%
2021 -NZ$2.47 Billion-13.21%
2020 -NZ$2.84 Billion72.69%
2019 -NZ$1.65 Billion36.01%
2018 -NZ$1.21 Billion616.83%
2017 -NZ$0.17 Billion-15.24%
2016 -NZ$0.2 Billion107.91%
2015 -NZ$95.72 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-NZ$31.11 Million-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$0.42 Billion-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA